Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 5/20 | 0.66 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.66 |
| ▸ | TP53 | P04637 | 3/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | TNKS | O95271 | 2/20 | 0.57 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12791230 | 0.83 | LMNA (0.72) | POLBLMNAKDM4EMEN1HPGD | |
| SCHEMBL6520217 | 0.82 | KMT2A (0.71) | POLBLMNAKDM4EMEN1HPGD | |
| SCHEMBL6520187 | 0.79 | MAPT (0.55) | POLBLMNAKDM4EMEN1HPGD | |
| SCHEMBL3869028 | 0.75 | TNKS (0.67) | POLBLMNAKDM4EMEN1HPGD | |
| SCHEMBL12549629 | 0.72 | TNKS (1.00) | POLBLMNAKDM4EMEN1HPGD | |
| SCHEMBL3873940 | 0.71 | NPSR1 (0.42) | POLBLMNAKDM4EMEN1HPGD | |
| SCHEMBL12791473 | 0.70 | MEN1 (0.55) | POLBLMNAKDM4EMEN1HPGD | |
| SCHEMBL15462269 | 0.69 | TNKS (0.61) | POLBLMNAKDM4EMEN1HPGD | |
| SCHEMBL12549503 | 0.69 | TNKS (0.59) | POLBLMNAKDM4EMEN1HPGD | |
| SCHEMBL2354757 | 0.69 | KMT2A (0.58) | POLBLMNAKDM4EMEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065703-A1 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | VM THERAPEUTICS LLC | 2011-03-17 | — | — | US | claimed |
| US-8586619-B2 | Agents of calcium ion channel modulators | VM THERAPEUTICS LLC (US) | 2013-11-19 | — | — | US | disclosed |
| US-8586619-B2 | Agents of calcium ion channel modulators | VM THERAPEUTICS LLC (US) | 2013-11-19 | — | — | US | disclosed |
| US-20110065703-A1 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | VM THERAPEUTICS LLC | 2011-03-17 | — | — | US | disclosed |
| US-20110065703-A1 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | VM THERAPEUTICS LLC | 2011-03-17 | — | — | US | disclosed |
| US-20110065703-A1 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | VM THERAPEUTICS LLC | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065703-A1 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | CACNA1G, CACNA1C, CACNA1B | POLB 4842/4885LMNA 2068/4885KDM4E 3352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.